It is estimated that about one-third of Americans are clinically obese, with 25.8 million diagnosed with diabetes. It is no secret that the American culture has encouraged obesity and as a result reported cases of diabetes is on the rise.
Scientists are still hard at work looking for a cure to both epidemics. One therapy looked at is using cannabinoids. Below you will see studies that back up the strongly held belief that cannabis is a natural cure to many illnesses that should be legalized for all. Please feel free to spread the truth ~ Cherry Girl
The Endocannabinoid System As A Target For Obesity Treatment
Overweight and obesity are major factors contributing to the development of type 2 diabetes mellitus (DM) and cardiovascular disease (CVD)… researchers and clinicians continue to explore pharmacotherapy, with intense efforts being directed toward the development of agents that will reduce weight and simultaneously reduce or eliminate modifiable cardiovascular and metabolic risk factors. Amongthe promising new agents are the CB(1) receptor antagonists. These agents target receptors of the endocannabinoid system, a neuromodulatory system recently found to influence energy balance, eating behavior, and metabolic homeostasis via central and peripheral mechanisms. In animal and clinical studies, antagonism of CB(1) receptors has resulted in meaningful weight loss and improvement of lipid and glycemic profiles.
ANTIOBESITY EFFICACY OF LH-21, A CANNABINOID CB(1) RECEPTOR ANTAGONIST WITH POOR BRAIN PENETRATION, IN DIET-INDUCED OBESE RATS
The peripheral blockade of cannabinoid CB(1) receptors has been proposed as a safe and effective therapy against obesity, putatively devoid of the adverse psychiatric side effects…Conclusions and implications: These results support the hypothesis that the treatment with the peripherally neutral acting cannabinoid CB(1) receptor antagonist, LH-21, may promote weight loss through modulation of visceral adipose tissue.
The Endocannabinoid System: A Promising Target For The Management Of Type 2 Diabetes
The endoCANNABINOID system “regulates the intake of nutrients through central mechanisms located within the hypothalamus and limbic area, but also intervenes in transport, metabolism and deposit of the nutrients in the digestive tract, liver, adipose tissue, skeletal muscle, and possibly pancreas. Activation of both central and peripheral CB1 receptors promotes weight gain and associated metabolicchanges. Conversely, selective CB(1) receptor antagonists, have been shown to reduce body weight, waist circumference, triglycerides, blood pressure, insulin resistance and C-reactive protein levels, and to increase HDL cholesterol and adiponectin concentrations in both non-diabetic and diabetic overweight/obese patients.
The Implication of CNR1 Gene’s Polymorphisms In The Modulation Of Endocannabinoid System Effects
The endocannabinoid system (ECS) represents one of the most important physiologic systems involved in organism homeostasis…The discovery of ECS and its signaling pathways opens a door towards the understanding of several important physiologic processes regarding appetite, food intake, metabolism, weight gain, motor control, memory, learning, drug addiction and nociception. The detailed analysis and validation of the ECS functioning can bring us very close to the discovery of new diagnosis and treatment methods for obesity, drugs abuse and numerous psychic diseases.
Rehashing Endocannabinoid Antagonists: Can We Selectively Target The Periphery To Safely Treat Obesity And Type 2 Diabetes?
A growing body of evidence supports an important role for the endocannabinoid system as a regulator of appetite, body weight, and systemic metabolism, which is overactive in obesity and type 2 diabetes. While initial attempts to target this system using rimonabant were successful in producing weight loss and improving obesity-related metabolic complications in humans, adverse central nervous system side effects precluded introduction of this drug into clinical practice. However, new data, presented by Tam and colleagues, demonstrate that selective blockade of peripheral cannabinoid receptors may be a novel successful therapeutic approach.
Pharmacotherapeutic Targeting Of The Endocannabinoid Signaling System: Drugs For Obesity And The Metabolic Syndrome.
Endogenous signaling lipids (“endocannabinoids”) functionally related to Delta(9)-tetrahydrocannabinol, the psychoactive ingredient of marijuana (Cannabis), are important biomediators and metabolic regulators critical to mammalian (patho)physiology.More recent data support the concept that the endocananbinoid system may be modulated for therapeutic gain at discrete pharmacological targets with safety and efficacy.Pressing worldwide healthcare needs and increasing appreciation of endocannabinoid biology make the rational design and refinement of targeted CB1 receptor modulators a promising route to future medications with significant therapeutic impact against overweight, obesity, obesity-related cardiometabolic dysregulation, and, more generally, maladies having a reward-supported appetitive component.